DUBLIN, March 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda ® (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).
The Appeals Court found that the U.S. District Court for the Southern District of Florida did not correctly construe the claims of the '720 Patent, and remanded the case to the District Court for further proceedings using claim constructions consistent with the Appeals Court's ruling.
Actavis' Abbreviated New Drug Application for its generic version of Lialda ® is currently pending with the U.S. Food and Drug Administration (FDA).
Lialda ® is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC. For the 12 months ended January 31, 2014 total U.S. sales of Lialda ® were approximately $576 million, according to IMS Health.About Actavis Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA. Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries. The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts